{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T21:09:18Z","timestamp":1788728958397,"version":"build-2803163510"},"reference-count":231,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,8,5]],"date-time":"2027-08-05T00:00:00Z","timestamp":1817424000000},"content-version":"am","delay-in-days":277,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1R15AG091199-01"],"award-info":[{"award-number":["1R15AG091199-01"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.pharmthera.2026.109090","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T23:37:02Z","timestamp":1785368222000},"page":"109090","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors"],"prefix":"10.1016","volume":"287","author":[{"given":"Natalia Motzko","family":"Noto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Fidelia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur S.","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi X.","family":"Cubeddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narasimman","family":"Gurusamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Speth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040571","article-title":"Insights into exosome transport through the blood-brain barrier and the potential Therapeutical applications in brain diseases","volume":"16","author":"Abdelsalam","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajmo.2025.100115","article-title":"The impact of different antidiabetic drugs on fracture risk in patients with type 2 diabetes mellitus: A systematic review and network Meta-analysis of randomized controlled trials with a focus on SGLT2 inhibitors","volume":"14","author":"Admani","year":"2025","journal-title":"American Journal of Medicine Open"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0015","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/dom.12881","article-title":"Determinants of the increase in ketone concentration during SGLT2 inhibition in NGT, IFG and T2DM patients","volume":"19","author":"Al Jobori","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0020","series-title":"Why is dementia different for women?","author":"Alzheimer's Society","year":"2025"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0025","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.smhs.2019.08.006","article-title":"Physical activity, exercise, and chronic diseases: A brief review","volume":"1","author":"Anderson","year":"2019","journal-title":"Sports Medicine and Health Science"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0030","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1212\/WNL.53.7.1488","article-title":"Sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample","volume":"53","author":"Andreasen","year":"1999","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0035","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1021\/acschemneuro.0c00722","article-title":"Targeting ROS-dependent AKT\/GSK-3\u03b2\/NF-\u03baB and DJ-1\/Nrf2 pathways by Dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced Parkinson\u2019s disease rat model","volume":"12","author":"Arab","year":"2021","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0040","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.cbi.2017.08.013","article-title":"Canagliflozin prevents scopolamine-induced memory impairment in rats: Comparison with galantamine hydrobromide action","volume":"277","author":"Arafa","year":"2017","journal-title":"Chemico-Biological Interactions"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0045","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1007\/s00125-016-4134-x","article-title":"Empagliflozin decreases myocardial cytoplasmic Na(+) through inhibition of the cardiac Na(+)\/H(+) exchanger in rats and rabbits","volume":"60","author":"Baartscheer","year":"2017","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0050","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/dom.13670","article-title":"Uric acid and the cardio-renal effects of SGLT2 inhibitors","volume":"21","author":"Bailey","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0055","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11892-021-01442-z","article-title":"Renal protection with SGLT2 inhibitors: Effects in acute and chronic kidney disease","volume":"22","author":"Bailey","year":"2022","journal-title":"Current Diabetes Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0060","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1124\/jpet.116.235069","article-title":"Empagliflozin protects against diet-induced NLRP-3 Inflammasome activation and lipid accumulation","volume":"359","author":"Benetti","year":"2016","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0065","doi-asserted-by":"crossref","DOI":"10.1177\/03000605241227659","article-title":"Plausible prediction of renoprotective effects of sodium-glucose cotransporter-2 inhibitors in patients with chronic kidney diseases","volume":"52","author":"Berezin","year":"2024","journal-title":"The Journal of International Medical Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109090_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12081827","article-title":"Trajectory of Irisin as a predictor of kidney-related outcomes in patients with asymptomatic heart failure","volume":"12","author":"Berezina","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0075","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s12325-023-02683-y","article-title":"Predictors of kidney function outcomes and their relation to SGLT2 inhibitor Dapagliflozin in patients with type 2 diabetes mellitus who had chronic heart failure","volume":"41","author":"Berezina","year":"2024","journal-title":"Advances in Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0080","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1097\/01.mnh.0000174146.52915.5d","article-title":"Na+\/H+ exchangers: Physiology and link to hypertension and organ ischemia","volume":"14","author":"Bobulescu","year":"2005","journal-title":"Current Opinion in Nephrology and Hypertension"},{"issue":"7382","key":"10.1016\/j.pharmthera.2026.109090_bb0085","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10777","article-title":"A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis","volume":"481","author":"Bostrom","year":"2012","journal-title":"Nature"},{"issue":"7382","key":"10.1016\/j.pharmthera.2026.109090_bb0090","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nature10777","article-title":"A PGC1-\u03b1-dependent myokine that drives brown-fat-like development of white fat and thermogenesis","volume":"481","author":"Bostr\u00f6m","year":"2012","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0095","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12933-017-0516-8","article-title":"Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: A pilot study","volume":"16","author":"Bouchi","year":"2017","journal-title":"Cardiovascular Diabetology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0100","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/nan.12711","article-title":"Irisin treatment lowers levels of phosphorylated tau in the hippocampus of pre-symptomatic female but not male htau mice","volume":"47","author":"Bretland","year":"2021","journal-title":"Neuropathology and Applied Neurobiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0105","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circulation. Heart Failure"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0110","first-page":"347","article-title":"Empagliflozin prevents worsening of cardiac function in an experimental model of pressure overload-induced heart failure","volume":"2","author":"Byrne","year":"2017","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101553","article-title":"Empagliflozin activates Wnt\/\u03b2-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance against type-3 cardiorenal syndrome","volume":"64","author":"Cai","year":"2022","journal-title":"Molecular Metabolism"},{"issue":"15","key":"10.1016\/j.pharmthera.2026.109090_bb0120","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13098-024-01346-4","article-title":"The relationship between diabetes and the dementia risk: A meta-analysis","volume":"16","author":"Cao","year":"2024","journal-title":"Diabetology and Metabolic Syndrome"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0130","series-title":"Type 2 diabetes","author":"CDC","year":"2024"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0135","doi-asserted-by":"crossref","first-page":"4","DOI":"10.2337\/diaclin.32.1.4","article-title":"SGLT-2 inhibitors: A new mechanism for glycemic control","volume":"32","author":"Chao","year":"2014","journal-title":"Clinical Diabetes"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0140","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s12195-016-0458-3","article-title":"Elucidation of exosome migration across the blood-brain barrier model in vitro","volume":"9","author":"Chen","year":"2016","journal-title":"Cellular and Molecular Bioengineering"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0145","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12933-022-01480-1","article-title":"Direct cardiac effects of SGLT2 inhibitors","volume":"21","author":"Chen","year":"2022","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0150","article-title":"Effect of semaglutide and empagliflozin on cognitive function and hippocampal phosphoproteomic in obese mice","volume":"14","author":"Chen","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155292","article-title":"Irisin promotes osteogenic differentiation of bone marrow mesenchymal stem cells by activating autophagy via the Wnt\/\/\u03b2-catenin signal pathway","volume":"136","author":"Chen","year":"2020","journal-title":"Cytokine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0160","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1007\/s00125-021-05407-5","article-title":"Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: An analysis from the randomised VERTIS CV trial","volume":"64","author":"Cherney","year":"2021","journal-title":"Diabetologia"},{"issue":"43","key":"10.1016\/j.pharmthera.2026.109090_bb0165","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1093\/eurheartj\/ehac431","article-title":"Exerkine fibronectin type-III domain-containing protein 5\/irisin-enriched extracellular vesicles delay vascular ageing by increasing SIRT6 stability","volume":"43","author":"Chi","year":"2022","journal-title":"European Heart Journal"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0170","series-title":"Renal Osteodystrophy","author":"Cleveland Clinic","year":"2025"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0175","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1038\/s41598-017-02557-8","article-title":"Irisin prevents and restores bone loss and muscle atrophy in hind-limb suspended mice","volume":"7","author":"Colaianni","year":"2017","journal-title":"Scientific Reports"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0180","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.2337\/dc16-1728","article-title":"Physical activity\/exercise and diabetes: A position statement of the American Diabetes Association","volume":"39","author":"Colberg","year":"2016","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0185","first-page":"27","article-title":"Empagliflozin improves diastolic function in a nondiabetic rodent model of heart failure with preserved ejection fraction","volume":"4","author":"Connelly","year":"2019","journal-title":"JACC: Basic to Translational Science"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0200","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1530\/EJE-14-0204","article-title":"Plasma irisin levels progressively increase in response to increasing exercise workloads in young, healthy, active subjects","volume":"171","author":"Daskalopoulou","year":"2014","journal-title":"European Journal of Endocrinology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0205","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s11011-024-01478-6","article-title":"The SGLT2 inhibitor empagliflozin exerts neuroprotective effect against hydrogen peroxide-induced toxicity on primary neurons","volume":"40","author":"Davri","year":"2024","journal-title":"Metabolic Brain Disease"},{"issue":"S1","key":"10.1016\/j.pharmthera.2026.109090_bb0210","doi-asserted-by":"crossref","DOI":"10.1002\/alz.085413","article-title":"Physical exercise upregulates Irisin in extracellular vesicles","volume":"20","author":"De Felice","year":"2024","journal-title":"Alzheimer\u2019s & Dementia"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0215","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/cbin.11441","article-title":"Irisin ameliorates high glucose-induced cardiomyocytes injury via AMPK\/mTOR signal pathway","volume":"44","author":"Deng","year":"2020","journal-title":"Cell Biology International"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0220","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/ana.26946","article-title":"Irisin levels in cerebrospinal fluid correlate with biomarkers and clinical dementia scores in Alzheimer disease","volume":"96","author":"Dicarlo","year":"2024","journal-title":"Annals of Neurology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0225","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/ana.22055","article-title":"Atherosclerosis, dementia, and Alzheimer disease in the Baltimore longitudinal study of aging cohort","volume":"68","author":"Dolan","year":"2010","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0230","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.brainresbull.2022.01.017","article-title":"Dapagliflozin diminishes memory and cognition impairment in Streptozotocin induced diabetes through its effect on Wnt\/\u03b2-Catenin and CREB pathway","volume":"181","author":"El-Safty","year":"2022","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0235","doi-asserted-by":"crossref","DOI":"10.2174\/011573403X435290251201095734","article-title":"SGLT2 inhibitors as mitochondrial therapies in heart failure: A bioenergetic revolution in Cardiometabolic medicine","author":"Epelde","year":"2026","journal-title":"Current Cardiology Reviews"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0240","doi-asserted-by":"crossref","first-page":"R113","DOI":"10.1530\/EJE-17-0832","article-title":"Mechanisms in endocrinology: SGLT2 inhibitors: Clinical benefits by restoration of normal diurnal metabolism?","volume":"178","author":"Esterline","year":"2018","journal-title":"European Journal of Endocrinology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0245","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.carpath.2005.01.005","article-title":"Cardiac remodeling and failure from molecules to man (part II)","volume":"14","author":"Fedak","year":"2005","journal-title":"Cardiovascular Pathology"},{"issue":"1105","key":"10.1016\/j.pharmthera.2026.109090_bb0250","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20190562","article-title":"Non-invasive assessment of early stage diabetic nephropathy by DTI and bold MRI","volume":"93","author":"Feng","year":"2020","journal-title":"The British Journal of Radiology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0255","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2337\/dc16-2724","article-title":"Renal handling of ketones in response to sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes","volume":"40","author":"Ferrannini","year":"2017","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0260","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.2337\/db15-1356","article-title":"Shift to fatty substrate utilization in response to sodium-glucose cotransporter 2 inhibition in subjects without diabetes and patients with type 2 diabetes","volume":"65","author":"Ferrannini","year":"2016","journal-title":"Diabetes"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0265","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.2337\/dc16-0330","article-title":"CV protection in the EMPA-REG outcome trial: A \u201cthrifty substrate\u201d hypothesis","volume":"39","author":"Ferrannini","year":"2016","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0270","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"The Journal of Clinical Investigation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0275","doi-asserted-by":"crossref","first-page":"9062","DOI":"10.1038\/s41598-022-13054-y","article-title":"Renal protection induced by physical exercise may be mediated by the irisin\/AMPK axis in diabetic nephropathy","volume":"12","author":"Formigari","year":"2022","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0280","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1177\/1479164114561992","article-title":"Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences","volume":"12","author":"Gallo","year":"2015","journal-title":"Diabetes & Vascular Disease Research"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104215","article-title":"Cardiorenal protection of SGLT2 inhibitors-perspectives from metabolic reprogramming","volume":"83","author":"Gao","year":"2022","journal-title":"EBioMedicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0290","doi-asserted-by":"crossref","first-page":"382","DOI":"10.2337\/diacare.24.2.382","article-title":"Renal gluconeogenesis: Its importance in human glucose homeostasis","volume":"24","author":"Gerich","year":"2001","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0295","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1172\/JCI22831","article-title":"Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment","volume":"114","author":"Gong","year":"2004","journal-title":"The Journal of Clinical Investigation"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0300","doi-asserted-by":"crossref","first-page":"656","DOI":"10.21873\/invivo.13864","article-title":"Effect of hypoxia on Irisin secretion by human cardiomyocytes","volume":"39","author":"Grzeszczuk","year":"2025","journal-title":"In Vivo"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0305","doi-asserted-by":"crossref","DOI":"10.3390\/cells13030277","article-title":"The role of FNDC5\/Irisin in cardiovascular disease [review]","volume":"13","author":"Grzeszczuk","year":"2024","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0310","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1002\/biof.1998","article-title":"Dapagliflozin improves diabetic cognitive impairment via indirectly modulating the mitochondria homeostasis of hippocampus in diabetic mice","volume":"50","author":"Gui","year":"2024","journal-title":"Biofactors"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109090_bb0315","doi-asserted-by":"crossref","DOI":"10.3390\/metabo12100925","article-title":"Betatrophin and insulin resistance","volume":"12","author":"Guo","year":"2022","journal-title":"Metabolites"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0320","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/dom.13833","article-title":"A 96-week, multinational, randomized, double-blind, parallel-group, clinical trial evaluating the safety and effectiveness of bexagliflozin as a monotherapy for adults with type 2 diabetes","volume":"21","author":"Halvorsen","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0325","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12944-022-01727-6","article-title":"Irisin protects against obesity-related chronic kidney disease by regulating perirenal adipose tissue function in obese mice","volume":"21","author":"Han","year":"2022","journal-title":"Lipids in Health and Disease"},{"issue":"Pt 2","key":"10.1016\/j.pharmthera.2026.109090_bb0330","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1242\/jcs.018093","article-title":"Integrin signalling at a glance","volume":"122","author":"Harburger","year":"2009","journal-title":"Journal of Cell Science"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcte.2024.100335","article-title":"SGLT2 inhibitors: Beyond glycemic control","volume":"35","author":"Hasan","year":"2024","journal-title":"Journal of Clinical & Translational Endocrinology"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0340","doi-asserted-by":"crossref","first-page":"2784","DOI":"10.2337\/db16-0058","article-title":"The Na+\/glucose cotransporter inhibitor Canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels","volume":"65","author":"Hawley","year":"2016","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0345","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci9030057","article-title":"Empagliflozin ameliorates type 2 diabetes-induced ultrastructural remodeling of the neurovascular unit and neuroglia in the female db\/db mouse","volume":"9","author":"Hayden","year":"2019","journal-title":"Brain Sciences"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0350","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1007\/s00125-019-4859-4","article-title":"Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease","volume":"62","author":"Heerspink","year":"2019","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0355","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s13105-021-00845-6","article-title":"Swimming exercise versus L-carnosine supplementation for Alzheimer\u2019s dementia in rats: Implication of circulating and hippocampal FNDC5\/irisin","volume":"78","author":"Hegazy","year":"2022","journal-title":"Journal of Physiology and Biochemistry"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0360","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s13195-020-00607-4","article-title":"Empagliflozin reduces vascular damage and cognitive impairment in a mixed murine model of Alzheimer\u2019s disease and type 2 diabetes","volume":"12","author":"Hierro-Bujalance","year":"2020","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2026.109090_bb0365","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.neurobiolaging.2011.09.003","article-title":"CSF biomarkers for Alzheimer\u2019s disease: Current utility and potential future use","volume":"32","author":"Holtzman","year":"2011","journal-title":"Neurobiology of Aging"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0370","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s11255-014-0656-7","article-title":"Perirenal fat associated with microalbuminuria in obese rats","volume":"46","author":"Hou","year":"2014","journal-title":"International Urology and Nephrology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0375","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MED.0000000000000311","article-title":"An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus","volume":"24","author":"Hsia","year":"2017","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0380","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-023-01816-5","article-title":"Insights into SGLT2 inhibitor treatment of diabetic cardiomyopathy: Focus on the mechanisms [review]","volume":"22","author":"Huang","year":"2023","journal-title":"Cardiovascular Diabetology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0385","doi-asserted-by":"crossref","DOI":"10.1002\/cbf.70075","article-title":"Irisin is a potential novel biomarker and therapeutic target against kidney diseases","volume":"43","author":"Huang","year":"2025","journal-title":"Cell Biochemistry and Function"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0390","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.673440","article-title":"Atherosclerosis: The culprit and co-victim of vascular dementia","volume":"15","author":"Huang","year":"2021","journal-title":"Frontiers in Neuroscience"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109090_bb0395","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/ijo.2014.42","article-title":"Irisin stimulates muscle growth-related genes and regulates adipocyte differentiation and metabolism in humans","volume":"38","author":"Huh","year":"2014","journal-title":"International Journal of Obesity"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0400","doi-asserted-by":"crossref","first-page":"E2154","DOI":"10.1210\/jc.2014-1437","article-title":"Exercise-induced irisin secretion is independent of age or fitness level and increased irisin may directly modulate muscle metabolism through AMPK activation","volume":"99","author":"Huh","year":"2014","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0405","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s40200-025-01824-0","article-title":"SGLT2 inhibitors and AMPK crosstalk in diabetes mellitus: Mechanistic insights and therapeutic applications","volume":"25","author":"Hushmandi","year":"2026","journal-title":"Journal of Diabetes and Metabolic Disorders"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0410","series-title":"About diabetes: Facts & figures","author":"International Diabetes Federation","year":"2026"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0415","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7555\/JBR.37.20230133","article-title":"Irisin\/BDNF signaling in the muscle-brain axis and circadian system: A review","volume":"38","author":"Inyushkin","year":"2023","journal-title":"Journal of Biomedical Research"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0420","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s11010-024-05076-z","article-title":"Empagliflozin and dapagliflozin decreased atrial monoamine oxidase expression and alleviated oxidative stress in overweight non-diabetic cardiac patients","volume":"480","author":"Ionic\u0103","year":"2025","journal-title":"Molecular and Cellular Biochemistry"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0425","doi-asserted-by":"crossref","first-page":"463","DOI":"10.4239\/wjd.v15.i3.463","article-title":"Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience","volume":"15","author":"Islam","year":"2024","journal-title":"World Journal of Diabetes"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109090_bb0430","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1038\/s42255-021-00438-z","article-title":"Exercise hormone irisin is a critical regulator of cognitive function","volume":"3","author":"Islam","year":"2021","journal-title":"Nature Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0435","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibitors: Benefits versus risk","volume":"15","author":"Jasleen","year":"2023","journal-title":"Cureus"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0440","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.cmet.2015.08.001","article-title":"Detection and quantitation of circulating human Irisin by tandem mass spectrometry","volume":"22","author":"Jedrychowski","year":"2015","journal-title":"Cell Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0445","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines12051098","article-title":"Diabetes and renal complications: An overview on pathophysiology, biomarkers and therapeutic interventions","volume":"12","author":"Jha","year":"2024","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0450","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1053\/j.ajkd.2011.10.008","article-title":"Exercise in individuals with CKD","volume":"59","author":"Johansen","year":"2012","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0455","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s12576-018-0619-3","article-title":"Effects of running a marathon on irisin concentration in men aged over 50","volume":"69","author":"J\u00f3\u017ak\u00f3w","year":"2019","journal-title":"The Journal of Physiological Sciences"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109090_bb0460","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1177\/09603271211010906","article-title":"Effect of taxifolin\/dapagliflozin combination on colistin-induced nephrotoxicity in rats","volume":"40","author":"Kabel","year":"2021","journal-title":"Human & Experimental Toxicology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0465","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2022.121002","article-title":"Boosting amygdaloid GABAergic and neurotrophic machinery via dapagliflozin-enhanced LKB1\/AMPK signaling in anxious demented rats","volume":"310","author":"Kamel","year":"2022","journal-title":"Life Sciences"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0470","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nm.3762","article-title":"Defective fatty acid oxidation in renal tubular epithelial cells has a key role in kidney fibrosis development","volume":"21","author":"Kang","year":"2015","journal-title":"Nature Medicine"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0475","first-page":"543","article-title":"Direct effects of Empagliflozin on extracellular matrix Remodelling in human cardiac Myofibroblasts: Novel translational clues to explain EMPA-REG OUTCOME results","volume":"36","author":"Kang","year":"2020","journal-title":"The Canadian Journal of Cardiology"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0480","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/j.cell.2018.10.025","article-title":"Irisin mediates effects on bone and fat via \u03b1V integrin receptors","volume":"175","author":"Kim","year":"2018","journal-title":"Cell"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109090_bb0485","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209805","article-title":"SGLT2 inhibitor use and risk of dementia and Parkinson disease among patients with type 2 diabetes","volume":"103","author":"Kim","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0490","article-title":"Glucocorticoid receptor positively regulates transcription of FNDC5 in the liver","volume":"7","author":"Kim","year":"2017","journal-title":"Scientific Reports"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0495","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/dom.13905","article-title":"Effect of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on gluconeogenesis in proximal renal tubules","volume":"22","author":"Kim","year":"2020","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0500","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1038\/s41467-020-15983-6","article-title":"SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease","volume":"11","author":"Kim","year":"2020","journal-title":"Nature Communications"},{"issue":"7 Suppl 1","key":"10.1016\/j.pharmthera.2026.109090_bb0505","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.3949\/ccjm.84.s1.03","article-title":"The essential role of exercise in the management of type 2 diabetes","volume":"84","author":"Kirwan","year":"2017","journal-title":"Cleveland Clinic Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0510","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.104870","article-title":"Empagliflozin protects heart from inflammation and energy depletion via AMPK activation","volume":"158","author":"Koyani","year":"2020","journal-title":"Pharmacological Research"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0515","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s00125-021-05424-4","article-title":"Sodium-glucose cotransporter 2 inhibitors and risk of nephrolithiasis","volume":"64","author":"Kristensen","year":"2021","journal-title":"Diabetologia"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0520","article-title":"The bidirectional link between diabetes and kidney disease: Mechanisms and management","volume":"15","author":"Kumar","year":"2023","journal-title":"Cureus"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0525","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDra2400265","article-title":"Pharmacologic therapies for type 2 diabetes","volume":"4","author":"Kuo","year":"2025","journal-title":"NEJM Evidence"},{"issue":"10","key":"10.1016\/j.pharmthera.2026.109090_bb0530","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202300420R","article-title":"Irisin ameliorates diabetic kidney disease by restoring autophagy in podocytes","volume":"37","author":"Lai","year":"2023","journal-title":"FASEB Journal"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0535","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1111\/dom.12127","article-title":"Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes","volume":"15","author":"Lambers Heerspink","year":"2013","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0540","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1007\/s11010-022-04633-8","article-title":"Metformin and empagliflozin modulate monoamine oxidase-related oxidative stress and improve vascular function in human mammary arteries","volume":"478","author":"Lascu","year":"2023","journal-title":"Molecular and Cellular Biochemistry"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0545","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.freeradbiomed.2017.01.035","article-title":"Dapagliflozin, a selective SGLT2 inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts","volume":"104","author":"Lee","year":"2017","journal-title":"Free Radical Biology & Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0550","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2337\/db17-1218","article-title":"Senescent T cells predict the development of hyperglycemia in humans","volume":"68","author":"Lee","year":"2019","journal-title":"Diabetes"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0555","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/6305735","article-title":"The SGLT-2 inhibitor dapagliflozin has a therapeutic effect on atherosclerosis in diabetic ApoE(\u2212\/\u2212) mice","volume":"2016","author":"Leng","year":"2016","journal-title":"Mediators of Inflammation"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0560","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12933-019-0816-2","article-title":"SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart","volume":"18","author":"Li","year":"2019","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0565","article-title":"Roles and mechanisms of Irisin in attenuating pathological features of osteoarthritis","volume":"9","author":"Li","year":"2021","journal-title":"Frontiers in Cell and Development Biology"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0570","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202503723R","article-title":"Combined empagliflozin and sacubitril\/valsartan therapy additively improves cardiorenal function through AMPK activation and angiotensin II type 1 receptor signaling attenuation in a rat model of cardiorenal syndrome","volume":"40","author":"Li","year":"2026","journal-title":"FASEB Journal"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0575","first-page":"15","article-title":"SGLT2 inhibitor, Canagliflozin, attenuates myocardial infarction in the diabetic and nondiabetic heart","volume":"4","author":"Lim","year":"2019","journal-title":"JACC: Basic to Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0580","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s12933-014-0148-1","article-title":"Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice","volume":"13","author":"Lin","year":"2014","journal-title":"Cardiovascular Diabetology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0585","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2021.06.013","article-title":"FNDC5\/Irisin attenuates diabetic cardiomyopathy in a type 2 diabetes mouse model by activation of integrin \u03b1V\/\u03b25-AKT signaling and reduction of oxidative\/nitrosative stress","volume":"160","author":"Lin","year":"2021","journal-title":"Journal of Molecular and Cellular Cardiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0590","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jdiacomp.2013.03.002","article-title":"Lower circulating irisin is associated with type 2 diabetes mellitus","volume":"27","author":"Liu","year":"2013","journal-title":"Journal of Diabetes and its Complications"},{"issue":"18","key":"10.1016\/j.pharmthera.2026.109090_bb0595","doi-asserted-by":"crossref","first-page":"449","DOI":"10.4239\/wjd.v7.i18.449","article-title":"Impact of diabetes mellitus on risk of cardiovascular disease and all-cause mortality: Evidence on health outcomes and antidiabetic treatment in United States adults","volume":"7","author":"Liu","year":"2016","journal-title":"World Journal of Diabetes"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0600","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000503919","article-title":"The effects of SGLT2 inhibitors on cardiovascular and renal outcomes in diabetic patients: A systematic review and Meta-analysis","volume":"10","author":"Lo","year":"2020","journal-title":"Cardiorenal Medicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0605","first-page":"632","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: A state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC: Basic to Translational Science"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0610","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1176\/appi.neuropsych.20240173","article-title":"Myokines and the brain: A novel neuromuscular endocrine loop","volume":"37","author":"L\u00f3pez-Ojeda","year":"2025","journal-title":"The Journal of Neuropsychiatry and Clinical Neurosciences"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0615","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2022.953991","article-title":"Irisin stimulates protective signaling pathways in rat hippocampal neurons","volume":"16","author":"Lourenco","year":"2022","journal-title":"Frontiers in Cellular Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0620","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41591-018-0275-4","article-title":"Exercise-linked FNDC5\/irisin rescues synaptic plasticity and memory defects in Alzheimer\u2019s models","volume":"25","author":"Lourenco","year":"2019","journal-title":"Nature Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0625","article-title":"Cerebrospinal fluid irisin correlates with amyloid-\u03b2, BDNF, and cognition in Alzheimer\u2019s disease","volume":"12","author":"Lourenco","year":"2020","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0630","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116007","article-title":"Irisin improves diabetic cardiomyopathy-induced cardiac remodeling by regulating GSDMD-mediated pyroptosis through MITOL\/STING signaling","volume":"171","author":"Lu","year":"2024","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0635","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2174\/0115701611319744250116092707","article-title":"Roles of Empagliflozin in diabetic cardiomyopathy: A review","volume":"23","author":"Luo","year":"2025","journal-title":"Current Vascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0640","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3389\/fphys.2019.01085","article-title":"Irisin exerts inhibitory effect on Adipogenesis through regulation of Wnt signaling","volume":"10","author":"Ma","year":"2019","journal-title":"Frontiers in Physiology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0645","doi-asserted-by":"crossref","first-page":"235","DOI":"10.5414\/CNP65235","article-title":"Renal osteodystrophy: What\u2019s in a name? Presentation of a clinically useful new model to interpret bone histologic findings","volume":"65","author":"Malluche","year":"2006","journal-title":"Clinical Nephrology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102018","article-title":"Diabetes-Alzheimer\u2019s connection in older age: SGLT2 inhibitors as promising modulators of disease pathways","volume":"90","author":"Mancinetti","year":"2023","journal-title":"Ageing Research Reviews"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0655","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.cmet.2012.08.012","article-title":"Energy intake and exercise as determinants of brain health and vulnerability to injury and disease","volume":"16","author":"Mattson","year":"2012","journal-title":"Cell Metabolism"},{"issue":"21","key":"10.1016\/j.pharmthera.2026.109090_bb0660","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0665","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s40035-024-00431-y","article-title":"SGLT2 inhibitors: A novel therapy for cognitive impairment via multifaceted effects on the nervous system","volume":"13","author":"Mei","year":"2024","journal-title":"Translational Neurodegeneration"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0670","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41390-020-01177-9","article-title":"The role of integrins in inflammation and angiogenesis","volume":"89","author":"Mezu-Ndubuisi","year":"2021","journal-title":"Pediatric Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109090_bb0675","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.13741","article-title":"Empagliflozin normalizes the size and number of mitochondria and prevents reduction in mitochondrial size after myocardial infarction in diabetic hearts","volume":"6","author":"Mizuno","year":"2018","journal-title":"Physiological Reports"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0680","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2017.08.005","article-title":"The diabetic heart utilizes ketone bodies as an energy source","volume":"77","author":"Mizuno","year":"2017","journal-title":"Metabolism"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0685","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/dom.12244","article-title":"Efficacy and safety of sodium glucose co-transport-2 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials","volume":"16","author":"Monami","year":"2014","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109090_bb0690","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: An analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"The Lancet Diabetes and Endocrinology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0695","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1016\/j.molcel.2023.05.008","article-title":"Irisin acts through its integrin receptor in a two-step process involving extracellular Hsp90\u03b1","volume":"83","author":"Mu","year":"2023","journal-title":"Molecular Cell"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0700","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/nutrit\/nuy001","article-title":"Fundamentals of glycogen metabolism for coaches and athletes","volume":"76","author":"Murray","year":"2018","journal-title":"Nutrition Reviews"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0705","series-title":"Diabetic kidney disease","author":"National Institute Of Diabetes and Digestive and Kidney Diseases","year":"2017"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0710","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"The New England Journal of Medicine"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0715","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/dom.12829","article-title":"Rationale, design and baseline characteristics of the CANagliflozin cardioVascular assessment study-renal (CANVAS-R): A randomized, placebo-controlled trial","volume":"19","author":"Neal","year":"2017","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0720","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1038\/s41598-024-59635-x","article-title":"P2X7 receptor knockout does not alter renal function or prevent angiotensin II-induced kidney injury in F344 rats","volume":"14","author":"Nespoux","year":"2024","journal-title":"Scientific Reports"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0725","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1097\/MNH.0000000000000584","article-title":"Renal effects of SGLT2 inhibitors: An update","volume":"29","author":"Nespoux","year":"2020","journal-title":"Current Opinion in Nephrology and Hypertension"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0730","article-title":"Possible renoprotective mechanisms of SGLT2 inhibitors","volume":"10","author":"Nishiyama","year":"2023","journal-title":"Frontiers in Medicine (Lausanne)"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0735","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/febs.12619","article-title":"The effects of acute and chronic exercise on PGC-1\u03b1, irisin and browning of subcutaneous adipose tissue in humans","volume":"281","author":"Norheim","year":"2014","journal-title":"The FEBS Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0740","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121367","article-title":"Irisin in blood increases transiently after single sessions of intense endurance exercise and heavy strength training","volume":"10","author":"Nygaard","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0745","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2022.101620","article-title":"Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism","volume":"66","author":"Op den Kamp","year":"2022","journal-title":"Molecular Metabolism"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0750","doi-asserted-by":"crossref","DOI":"10.1016\/j.jdiacomp.2020.107647","article-title":"Role of ketogenic starvation sensors in mediating the renal protective effects of SGLT2 inhibitors in type 2 diabetes","volume":"34","author":"Packer","year":"2020","journal-title":"Journal of Diabetes and its Complications"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0755","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/jamacardio.2017.2275","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with heart failure: Proposal of a novel mechanism of action","volume":"2","author":"Packer","year":"2017","journal-title":"JAMA Cardiology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0760","series-title":"StatPearls","article-title":"Sodium-glucose transport protein 2 (SGLT2) inhibitors","author":"Padda","year":"2025"},{"issue":"3\u20134","key":"10.1016\/j.pharmthera.2026.109090_bb0765","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000543533","article-title":"The impact of SGLT2 inhibitors on dementia onset in patients with type 2 diabetes: A meta-analysis of cohort studies","volume":"115","author":"Pan","year":"2025","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0770","doi-asserted-by":"crossref","DOI":"10.1016\/j.physbeh.2023.114134","article-title":"The sodium glucose co-transporter 2 inhibitor ertugliflozin for Alzheimer\u2019s disease: Inhibition of brain insulin signaling disruption-induced tau hyperphosphorylation","volume":"263","author":"Pang","year":"2023","journal-title":"Physiology & Behavior"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0775","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41419-022-04735-7","article-title":"Irisin protects against vascular calcification by activating autophagy and inhibiting NLRP3-mediated vascular smooth muscle cell pyroptosis in chronic kidney disease","volume":"13","author":"Pang","year":"2022","journal-title":"Cell Death & Disease"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0780","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-01259-6","article-title":"Targeting integrin pathways: Mechanisms and advances in therapy","volume":"8","author":"Pang","year":"2023","journal-title":"Signal Transduction and Targeted Therapy"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb0785","doi-asserted-by":"crossref","first-page":"457","DOI":"10.33549\/physiolres.934896","article-title":"The effects of different types of exercise on circulating Irisin levels in healthy individuals and in people with overweight, metabolic syndrome and type 2 diabetes","volume":"71","author":"Parada-S\u00e1nchez","year":"2022","journal-title":"Physiological Research"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0790","series-title":"StatPearls","article-title":"Chronic kidney disease-mineral bone disorder (CKD-MBD)","author":"Patel","year":"2026"},{"issue":"23","key":"10.1016\/j.pharmthera.2026.109090_bb0795","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26237213","article-title":"Neuroprotective effect of SGLT2 inhibitors","volume":"26","author":"Pawlos","year":"2021","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0800","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70235","article-title":"Irisin-mediated muscle-renal crosstalk as a protective mechanism against contrast-induced acute kidney injury via cGAS-STING signalling inhibition","volume":"15","author":"Peng","year":"2025","journal-title":"Clinical and Translational Medicine"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0805","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/nrendo.2016.221","article-title":"Physiology and role of irisin in glucose homeostasis [review]","volume":"13","author":"Perakakis","year":"2017","journal-title":"Nature Reviews Endocrinology"},{"issue":"24","key":"10.1016\/j.pharmthera.2026.109090_bb0810","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0815","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1093\/cvr\/cvae047","article-title":"SGLT2 inhibitors: From glucose-lowering to cardiovascular benefits","volume":"120","author":"Preda","year":"2024","journal-title":"Cardiovascular Research"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0820","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1080\/03008207.2025.2561655","article-title":"Dapagliflozin attenuates lipotoxic tenocyte injury via PPAR\u03b1 activation and irisin-driven antioxidant pathways","volume":"67","author":"Pyo","year":"2026","journal-title":"Connective Tissue Research"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0825","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.neuroscience.2022.07.018","article-title":"Irisin: A promising treatment for neurodegenerative diseases","volume":"498","author":"Qi","year":"2022","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0830","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/s41392-024-01756-w","article-title":"Peroxisome proliferator-activated receptor gamma coactivator-1 (PGC-1) family in physiological and pathophysiological process and diseases","volume":"9","author":"Qian","year":"2024","journal-title":"Signal Transduction and Targeted Therapy"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0835","article-title":"Irisin promotes osteoblast proliferation and differentiation via activating the MAP kinase signaling pathways","volume":"6","author":"Qiao","year":"2016","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0840","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jshs.2022.10.003","article-title":"Exercise sustains the hallmarks of health","volume":"12","author":"Qiu","year":"2023","journal-title":"Journal of Sport and Health Science"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0845","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13578-020-00413-3","article-title":"New insights into the cellular activities of Fndc5\/Irisin and its signaling pathways","volume":"10","author":"Rabiee","year":"2020","journal-title":"Cell & Bioscience"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0850","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1042\/BJ20082055","article-title":"AMPK and the biochemistry of exercise: Implications for human health and disease","volume":"418","author":"Richter","year":"2009","journal-title":"The Biochemical Journal"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0855","doi-asserted-by":"crossref","first-page":"447","DOI":"10.2174\/18715273113126660160","article-title":"Invokana (Canagliflozin) as a dual inhibitor of acetylcholinesterase and sodium glucose co-transporter 2: Advancement in Alzheimer\u2019s disease- diabetes type 2 linkage via an enzoinformatics study","volume":"13","author":"Rizvi","year":"2014","journal-title":"CNS & Neurological Disorders Drug Targets"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106062","article-title":"Cognitive impairment and type 2 diabetes mellitus: Focus of SGLT2 inhibitors treatment","volume":"176","author":"Rizzo","year":"2022","journal-title":"Pharmacological Research"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0865","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0097452","article-title":"P2X(7) receptor in the kidneys of diabetic rats submitted to aerobic training or to N-acetylcysteine supplementation [corrected]","volume":"9","author":"Rodrigues","year":"2014","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0870","doi-asserted-by":"crossref","DOI":"10.3390\/ph18030313","article-title":"Cardiac fibrosis: Mechanistic discoveries linked to SGLT2 inhibitors","volume":"18","author":"Rolski","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"10.1016\/j.pharmthera.2026.109090_bb0875","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.2337\/dc13-3055","article-title":"Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes","volume":"37","author":"Rosenstock","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0880","first-page":"314","article-title":"Measurement of serum irisin in the different stages of chronic kidney disease","volume":"10","author":"Sadeghi Shad","year":"2019","journal-title":"Caspian Journal of Internal Medicine"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0885","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122393","article-title":"Irisin: An unveiled bridge between physical exercise and a healthy brain","volume":"339","author":"Sadier","year":"2024","journal-title":"Life Sciences"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0890","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jjcc.2017.12.004","article-title":"A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity","volume":"71","author":"Sano","year":"2018","journal-title":"Journal of Cardiology"},{"issue":"47","key":"10.1016\/j.pharmthera.2026.109090_bb0895","doi-asserted-by":"crossref","first-page":"33738","DOI":"10.1074\/jbc.M113.516641","article-title":"The structure of Irisin reveals a novel Intersubunit \u03b2-sheet fibronectin type III (FNIII) dimer: Implications for receptor activation","volume":"288","author":"Schumacher","year":"2013","journal-title":"Journal of Biological Chemistry"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109090_bb0900","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1091\/mbc.8.12.2563","article-title":"Modulatory roles for integrin activation and the synergy site of fibronectin during matrix assembly","volume":"8","author":"Sechler","year":"1997","journal-title":"Molecular Biology of the Cell"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb0905","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12868-018-0465-5","article-title":"Neurovascular dysfunction in vascular dementia, Alzheimer\u2019s and atherosclerosis","volume":"19","author":"Shabir","year":"2018","journal-title":"BMC Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0910","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/6580195","article-title":"Emerging protective actions of PGC-1\u03b1 in diabetic nephropathy","volume":"2022","author":"She","year":"2022","journal-title":"Oxidative Medicine and Cellular Longevity"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0915","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/ajh\/hpz016","article-title":"Dapagliflozin attenuates cardiac remodeling in mice model of cardiac pressure overload","volume":"32","author":"Shi","year":"2019","journal-title":"American Journal of Hypertension"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0920","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1136\/jnnp.70.5.624","article-title":"Both total and phosphorylated tau are increased in Alzheimer\u2019s disease","volume":"70","author":"Sj\u00f6gren","year":"2001","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0925","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2025.1695075","article-title":"Comparative effects of SGLT2 inhibitors and incretin-based therapies on dementia risk in type 2 diabetes: A systematic review and meta-analysis","volume":"16","author":"Song","year":"2025","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb0930","doi-asserted-by":"crossref","DOI":"10.3390\/ph16111620","article-title":"Preclinical studies of Canagliflozin, a sodium-glucose co-transporter 2 inhibitor, and donepezil combined therapy in Alzheimer\u2019s disease","volume":"16","author":"Stanciu","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0935","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100988","article-title":"High cerebrospinal amyloid-\u03b2 42 is associated with normal cognition in individuals with brain amyloidosis","volume":"38","author":"Sturchio","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0940","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/nep.13860","article-title":"Update on diagnosis, pathophysiology, and management of diabetic kidney disease","volume":"26","author":"Sugahara","year":"2021","journal-title":"Nephrology (Carlton)"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0945","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1007\/s11255-013-0404-4","article-title":"Sonographic evaluation of Para- and perirenal fat thickness is an independent predictor of early kidney damage in obese patients","volume":"45","author":"Sun","year":"2013","journal-title":"International Urology and Nephrology"},{"issue":"1\u20133","key":"10.1016\/j.pharmthera.2026.109090_bb0950","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ejphar.2013.05.014","article-title":"Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice","volume":"715","author":"Tahara","year":"2013","journal-title":"European Journal of Pharmacology"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0955","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1111\/dom.13648","article-title":"Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis","volume":"21","author":"Toyama","year":"2019","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb0960","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1620\/tjem.233.135","article-title":"High-intensity exercise causes greater irisin response compared with low-intensity exercise under similar energy consumption","volume":"233","author":"Tsuchiya","year":"2014","journal-title":"The Tohoku Journal of Experimental Medicine"},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb0965","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.metabol.2015.05.010","article-title":"Resistance exercise induces a greater irisin response than endurance exercise","volume":"64","author":"Tsuchiya","year":"2015","journal-title":"Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0970","series-title":"JARDIANCE\u00ae (empagliflozin tablets)","author":"U.S. Food & Drug Administration","year":"2023"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb0975","doi-asserted-by":"crossref","first-page":"771","DOI":"10.34067\/KID.0000000000000425","article-title":"SGLT2 inhibitors and kidney protection: Mechanisms beyond Tubuloglomerular feedback","volume":"360","author":"Upadhyay","year":"2024","journal-title":"Kidney"},{"issue":"25","key":"10.1016\/j.pharmthera.2026.109090_bb0980","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","article-title":"Effect of SGLT2 inhibitors on cardiovascular outcomes across various patient populations","volume":"81","author":"Usman","year":"2023","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb0985","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s00125-017-4509-7","article-title":"Class effects of SGLT2 inhibitors in mouse cardiomyocytes and hearts: Inhibition of Na(+)\/H(+) exchanger, lowering of cytosolic Na(+) and vasodilation","volume":"61","author":"Uthman","year":"2018","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb0990","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/s41581-020-0256-y","article-title":"The tubular hypothesis of nephron filtration and diabetic kidney disease","volume":"16","author":"Vallon","year":"2020","journal-title":"Nature Reviews. Nephrology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb0995","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev-physiol-031620-095920","article-title":"Effects of SGLT2 inhibitors on kidney and cardiovascular function [review]","volume":"83","author":"Vallon","year":"2021","journal-title":"Annual Review of Physiology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2021.100966","article-title":"Targeting RGD-binding integrins as an integrative therapy for diabetic retinopathy and neovascular age-related macular degeneration","volume":"85","author":"Van Hove","year":"2021","journal-title":"Progress in Retinal and Eye Research"},{"issue":"12","key":"10.1016\/j.pharmthera.2026.109090_bb1005","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.2337\/dc16-1312","article-title":"Effect of Empagliflozin on left ventricular mass and diastolic function in individuals with diabetes: An important clue to the EMPA-Reg outcome trial?","volume":"39","author":"Verma","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1010","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1007\/s00125-018-4670-7","article-title":"SGLT2 inhibitors and mechanisms of cardiovascular benefit: A state-of-the-art review [review]","volume":"61","author":"Verma","year":"2018","journal-title":"Diabetologia"},{"issue":"20","key":"10.1016\/j.pharmthera.2026.109090_bb1015","doi-asserted-by":"crossref","first-page":"13217","DOI":"10.1073\/pnas.172504199","article-title":"Amyloid beta -peptide inhibition of the PKA\/CREB pathway and long-term potentiation: Reversibility by drugs that enhance cAMP signaling","volume":"99","author":"Vitolo","year":"2002","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1020","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2024.1496271","article-title":"The effects of aerobic exercise on 24-hour mean blood glucose levels measured by continuous glucose monitoring in type 2 diabetes: A meta-analysis","volume":"15","author":"Wang","year":"2024","journal-title":"Frontiers in Physiology"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb1025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12979-024-00437-0","article-title":"Irisin inhibits microglial senescence via TFAM-mediated mitochondrial metabolism in a mouse model of tauopathy","volume":"21","author":"Wang","year":"2024","journal-title":"Immunity & Ageing"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1030","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.atherosclerosis.2022.02.007","article-title":"Irisin alleviates vascular calcification by inhibiting VSMC osteoblastic transformation and mitochondria dysfunction via AMPK\/Drp1 signaling pathway in chronic kidney disease","volume":"346","author":"Wang","year":"2022","journal-title":"Atherosclerosis"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb1035","doi-asserted-by":"crossref","first-page":"H246","DOI":"10.1152\/ajpheart.00438.2021","article-title":"Luseogliflozin, a sodium-glucose cotransporter-2 inhibitor, reverses cerebrovascular dysfunction and cognitive impairments in 18-mo-old diabetic animals","volume":"322","author":"Wang","year":"2022","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1040","doi-asserted-by":"crossref","DOI":"10.1016\/j.exger.2025.112935","article-title":"SGLT2 inhibitor, bone metabolism biomarkers, and osteoporosis risk: A Mendelian randomization study","volume":"211","author":"Wang","year":"2025","journal-title":"Experimental Gerontology"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb1045","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/ki.2014.111","article-title":"Histone deacetylase 4 selectively contributes to podocyte injury in diabetic nephropathy","volume":"86","author":"Wang","year":"2014","journal-title":"Kidney International"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb1050","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"The New England Journal of Medicine"},{"issue":"8","key":"10.1016\/j.pharmthera.2026.109090_bb1055","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.2337\/dc18-0277","article-title":"Diabetes and trajectories of estimated glomerular filtration rate: A prospective cohort analysis of the atherosclerosis risk in communities study","volume":"41","author":"Warren","year":"2018","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb1060","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27031118","article-title":"FNDC5\/Irisin: Physiology and pathophysiology","volume":"27","author":"Waseem","year":"2022","journal-title":"Molecules"},{"issue":"4","key":"10.1016\/j.pharmthera.2026.109090_bb1065","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb1070","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/j.cmet.2013.09.008","article-title":"Exercise induces hippocampal BDNF through a PGC-1\u03b1\/FNDC5 pathway","volume":"18","author":"Wrann","year":"2013","journal-title":"Cell Metabolism"},{"issue":"1","key":"10.1016\/j.pharmthera.2026.109090_bb1075","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13195-025-01929-x","article-title":"Comparative dementia risk with GLP1 receptor agonists, SGLT2 inhibitors, or DPP4 inhibitors: A population-based cohort study","volume":"17","author":"Wu","year":"2025","journal-title":"Alzheimer\u2019s Research & Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb1080","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.184468","article-title":"Aerobic exercise prevents renal osteodystrophy via irisin-activated osteoblasts","volume":"10","author":"Wu","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1085","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2021.745058","article-title":"Empagliflozin induces White adipocyte Browning and Modulates mitochondrial dynamics in KK Cg-Ay\/J mice and mouse adipocytes","volume":"12","author":"Xu","year":"2021","journal-title":"Frontiers in Physiology"},{"issue":"2","key":"10.1016\/j.pharmthera.2026.109090_bb1090","doi-asserted-by":"crossref","first-page":"572","DOI":"10.7150\/ijbs.63505","article-title":"Myokine Irisin promotes osteogenesis by activating BMP\/SMAD signaling via \u03b1V integrin and regulates bone mass in mice","volume":"18","author":"Xue","year":"2022","journal-title":"International Journal of Biological Sciences"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1095","article-title":"Current understanding of sodium-glucose transporter 2 inhibitors in cardiovascular-kidney-metabolic syndrome","volume":"17","author":"Yang","year":"2026","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1100","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109526","article-title":"The major molecular mechanisms mediating the renoprotective effects of SGLT2 inhibitors: An update","volume":"120","author":"Yaribeygi","year":"2019","journal-title":"Biomedicine & Pharmacotherapy"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb1105","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10557-018-6837-3","article-title":"Dapagliflozin attenuates Na(+)\/H(+) Exchanger-1 in Cardiofibroblasts via AMPK activation","volume":"32","author":"Ye","year":"2018","journal-title":"Cardiovascular Drugs and Therapy"},{"issue":"5","key":"10.1016\/j.pharmthera.2026.109090_bb1110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1042\/CS20190016","article-title":"FNDC5\/Irisin inhibits pathological cardiac hypertrophy","volume":"133","author":"Yu","year":"2019","journal-title":"Clinical Science (London, England)"},{"issue":"6","key":"10.1016\/j.pharmthera.2026.109090_bb1115","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.ejcb.2015.04.002","article-title":"Cardiac differentiation of mouse embryonic stem cells is influenced by a PPAR \u03b3\/PGC-1\u03b1-FNDC5 pathway during the stage of cardiac precursor cell formation","volume":"94","author":"Zadegan","year":"2015","journal-title":"European Journal of Cell Biology"},{"issue":"3","key":"10.1016\/j.pharmthera.2026.109090_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2025.189300","article-title":"Exosomes: Traversing the blood-brain barrier and their therapeutic potential in brain cancer","volume":"1880","author":"Zhang","year":"2025","journal-title":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"},{"issue":"36","key":"10.1016\/j.pharmthera.2026.109090_bb1125","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000030310","article-title":"A review of cardiovascular benefits of SGLT2 inhibitors","volume":"101","author":"Zhang","year":"2022","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1130","article-title":"Irisin attenuates cardiac injury and improves prognosis in rats with hemorrhagic shock by maintaining mitochondrial homeostasis via the AMPK\/Drp1 pathway","volume":"16","author":"Zhang","year":"2025","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1135","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.989135","article-title":"Irisin at the crossroads of inter-organ communications: Challenge and implications","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol (Lausanne)."},{"key":"10.1016\/j.pharmthera.2026.109090_bb1140","article-title":"Role of irisin in bone diseases","volume":"14","author":"Zhao","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"9","key":"10.1016\/j.pharmthera.2026.109090_bb1145","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1172\/JCI120849","article-title":"Mitochondrial dysfunction in pathophysiology of heart failure","volume":"128","author":"Zhou","year":"2018","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biology"},{"issue":"11","key":"10.1016\/j.pharmthera.2026.109090_bb1155","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1097\/GME.0000000000001388","article-title":"Lower circulating irisin in middle-aged and older adults with osteoporosis: A systematic review and meta-analysis","volume":"26","author":"Zhou","year":"2019","journal-title":"Menopause"},{"key":"10.1016\/j.pharmthera.2026.109090_bb1160","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109170","article-title":"Irisin rescues diabetic cardiac microvascular injury via ERK1\/2\/Nrf2\/HO-1 mediated inhibition of oxidative stress","volume":"183","author":"Zhu","year":"2022","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"22","key":"10.1016\/j.pharmthera.2026.109090_bb1165","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"The New England Journal of Medicine"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T20:23:35Z","timestamp":1788726215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":231,"alternative-id":["S0163725826001178"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109090","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Irisin upregulation as a contributory mechanism for the therapeutic benefits of SGLT-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109090","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109090"}}